title: Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer.
abstract: BACKGROUND
  Magnetic resonance imaging (MRI) has been increasingly utilized to screen and manage breast care. As the literature demonstrating its benefit expands, so do the potential clinical indications. However, routine review of the literature is merited to re-evaluate the appropriate and cost-effective use of MRI and guide clinicians in the areas of controversy.
  
  
  METHODS
  A literature review was performed to evaluate the current evidence for the use of MRI.
  
  
  RESULTS
  Evidence supports MRI screening for genetic mutation carriers and for those with an equivalent lifetime risk (>50%). Regarding staging and management, MRI is indicated for monitoring tumour response to neoadjuvant therapy. MRI should also be considered for patients with invasive lobular carcinoma, mammographically occult breast cancer and Paget's disease.
  
  
  CONCLUSIONS
  Though MRI is limited by moderate specificity and high cost, it can be a valuable, sensitive and cost-effective tool with thoughtful and judicious patient selection.
authors.affiliation: University of California, Department of Surgery, Division of Breast Surgical Oncology, San Francisco, CA 94115, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Zakhireh
authors.forename: Rachel
authors.initials: R
authors.lastname: Gomez
authors.forename: Laura
authors.initials: L
authors.lastname: Esserman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008403:Mass Screening / Q000379:methods*; D015414:Mastectomy, Subcutaneous; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging
chemical_list: D000970:Antineoplastic Agents